Suchergebnisse - "Carlo-Stella, Carmelo"

PubPharm (258)

21

Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation

enthalten in: Cancers | 2023

von Dei, D. | Lambri, N. | Stefanini, S. | +16

22

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients : The Italian VAX4FRAIL Study

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Corradini, P. | Agrati, C. | Apolone, G. | +125

23

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

enthalten in: Hematological oncology | 2023

von Carlo-Stella, C. | Zinzani, P. | Sureda, A. | +22

24

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

enthalten in: Frontiers in immunology | 2023

von Rescigno, M. | Agrati, C. | Salvarani, C. | +119

25

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma : A phase 1/2 study

enthalten in: Cancer Medicine | 2023

von Lesokhin, A. | LeBlanc, R. | Dimopoulos, M. | +18

26

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

enthalten in: Hematological Oncology | 2023

von Carlo‐Stella, C. | Zinzani, P. | Sureda, A. | +22

27

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

enthalten in: The New England journal of medicine | 2022

von Dickinson, M. | Carlo-Stella, C. | Morschhauser, F. | +18

CommentIn: N Engl J Med. 2022 Dec 15;387(24):2285-2286. - PMID 36507659

28

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Hamadani, M. | Chen, L. | Song, Y. | +4

29

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma : a subgroup analysis from the LOTIS-2 study

enthalten in: Blood advances | 2022

von Alderuccio, J. | Ai, W. | Radford, J. | +14

30

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

enthalten in: Blood | 2022

von Calabretta, E. | Hamadani, M. | Zinzani, P. | +2